Seres Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Seres Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.00126.337.13144.9333.2234.5128.27
Cost of Revenue3.5319.3413.43141.8990.570.000.00
Gross Profit-3.53-19.347.133.04-57.3634.510.00
Operating Expenses
Research & Development64.6098.26172.92141.8990.5780.1495.96
Selling, General & Administrative53.1877.5079.6969.2630.7824.7532.60
Operating Expenses117.78175.76253.6267.5330.78106.38128.55
Operating Income-121.32-195.10-246.49-64.49-88.13-71.88-100.28
Other Income/Expense
Interest Income3.977.303.062.870.950.001.17
Interest Expense0.00-2.476.02-2.91-2.920.000.00
Other Income/Expense-4.46-0.10-0.71-0.551.43-1.070.17
Income
Income Before Tax-125.77-190.13-250.16-65.58-89.13-70.28-98.94
Income Tax Expense0.000.000.000.000.000.000.00
Net Income0.14-113.72-250.16-65.58-89.13-70.28-98.94
Net Income - Continuous Operations0.14-190.13-183.58-65.580.000.000.00
Net Income - Discontinued Operations125.9176.41-66.580.000.000.000.00
EBITDA-120.30-188.85-237.51-58.55-81.55-62.07-91.08
EBIT-125.77-195.10-244.14-64.49-88.13-69.78-98.94
Depreciation & Amortization5.476.246.635.956.587.600.00
Earnings Per Share
Basic EPS-19.00-18.00-2.00-14.00-22.00-1.00-2.00
Diluted EPS-19.00-18.00-2.00-14.00-22.00-1.00-2.00
Basic Shares Outstanding7.776.40108.084.593.9956.6540.74
Diluted Shares Outstanding7.776.40108.084.593.9956.6540.74